Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

I'm wondering in the case of Covid trial

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Beachbum3232 Member Profile
 
Followed By 3
Posts 75
Boards Moderated 0
Alias Born 02/20/19
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2021 5:01:59 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/8/2021 4:32:22 PM
CEO's Presenting at Emerging Growth Conference Virtually Tomorrow InvestorsHub NewsWire - 6/8/2021 7:00:00 AM
CytoDyn's partner to submit request to conduct Phase 3 leronlimab studies in Brazil Seeking Alpha - 5/27/2021 6:33:58 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/24/2021 5:16:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2021 5:18:50 PM
CytoDyn promotes Antonio Migliarese to CFO role Seeking Alpha - 5/20/2021 5:14:56 PM
IQST Signals BUY InvestorsHub NewsWire - 5/20/2021 9:43:19 AM
CytoDyn to submit CD12 trial data to regulatory agencies in multiple countries Seeking Alpha - 5/18/2021 7:45:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2021 5:02:38 PM
CytoDyn plunges as FDA rebukes its clinical trials for COVID-19 therapy Seeking Alpha - 5/17/2021 3:51:07 PM
CytoDyn inks leronlimab distribution deal in India for COVID-19 Seeking Alpha - 5/13/2021 9:04:20 AM
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/10/2021 7:00:00 AM
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
Beachbum3232   Tuesday, 07/21/20 09:35:58 PM
Re: Amatuer17 post# 96722
Post # of 170689 
I'm wondering in the case of Covid trial if it's more important to establish safety first given all the underlying health problems maybe attributed to the enrolled patients even if they are mild/moderate, you know the doctor's oath of first do no harm so to speak. And if that's the case and the safety data could be retrieved sooner than the efficacy data, then why not tout it. I think there should have been more of "heads up" that this would be the case; I think we were led to believe top line results meant safety/efficacy and everything else. We also have a passionate CEO who is focused on saving lives vs. share price ---right now. That could change but I have heard him say in the past that sometimes saving lives is more important than share price----I'm paraphrasing and obviously it's not a popular position to have when you have many investors who have been waiting for this.

Folks I want this just as bad as anyone but clinical trials require patience I've worked in the industry for over 20 years and the one thing you can't rush is clinical trial results. Just my opinion.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences